Physician profile
Hemant Dhingra
NPI 1487672192
$5,890.67
in general payments reported to CMS, 2019-2025
32 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $296 · 2021: $207 · 2022: $632 · 2023: $649 · 2024: $2,879 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,680 · Consulting Fee: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,680.36 |
| Consulting Fee | $1,700.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,714.29 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Astrazeneca Pharmaceuticals Lp | $619.58 | 2022-2025 | Lokelma, Farxiga |
| Mallinckrodt Hospital Products INC. | $384.80 | 2022-2025 | Acthar |
| Octapharma USA, INC. | $251.62 | 2019-2020 | |
| Horizon Therapeutics Plc | $234.72 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $191.44 | 2019-2023 | Jynarque |
| Glaxosmithkline, LLC. | $186.41 | 2022-2024 | Benlysta, Jesduvroq |
| Bard Peripheral Vascular, INC. | $177.34 | 2019-2025 | Fluency Endovascular Stent Graft, Venovo, Covera |
| Novo Nordisk INC | $169.53 | 2023-2024 | |
| Fresenius USA Marketing, INC. | $167.41 | 2019-2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $128.18 | 2019-2025 | |
| Abbott Laboratories | $105.95 | 2019-2021 | |
| Travere Therapeutics, INC. | $82.30 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $65.36 | 2022-2023 | Lupkynis |
| Nxstage Medical, INC. | $65.09 | 2025 | Nxstage System One |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $56.79 | 2022-2023 | Tarpeyo |
| Vifor Pharma, INC. | $44.95 | 2022-2024 | Veltassa |
| Akebia Therapeutics INC | $40.80 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.94 | 2022-2023 | |
| Medtronic, INC. | $20.83 | 2022 | |
| Argon Medical Devices, INC. | $20.60 | 2020 | |
| Lilly USA, LLC | $20.04 | 2025 | Jardiance |
| Kyowa Kirin, INC. | $17.96 | 2024 | Crysvita |
| Amicus Therapeutics, INC. | $17.44 | 2019 | |
| Scpharmaceuticals INC. | $16.17 | 2024 | |
| Mozarc Medical US LLC | $15.87 | 2024 | Chameleon |
| Mallinckrodt Enterprises LLC | $15.75 | 2019 | |
| Genentech USA, INC. | $15.69 | 2025 | Gazyva |
| W. L. Gore & Associates, INC. | $11.82 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hemant Dhingra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.